Analysis on how to adjust the medication regimen after complete drug resistance to Mobosetinib (Anvili)

1. Therapeutic positioning and drug resistance issues of mobosetinib

Mobocertinib is an oral tyrosine kinase inhibitor (TKI) targeting EGFRexon 20 insertion mutation. It is mainly used for patients with non-small cell lung cancer who have previously received platinum-containing chemotherapy. Its listing fills the gap of long-term lack of effective targeted drugs for this mutated subtype. However, similar to other TKIs, after patients take moboxetinib for a period of time, tumor cells may develop resistance through multiple mechanisms, such as EGFR secondary mutations, activation of downstream signaling pathways (such as METamplification), activation of alternative pathways or phenotypic transformation (such as small cell lung cancer-like transformation). Once complete resistance occurs, continued use of mobosetinib alone will no longer be effective, and the treatment plan needs to be adjusted in a timely manner.

2. First-line strategy after drug resistance: combination therapy or replacement of targeted drugs

For patients who are resistant to mobosetinib, the first step is usually to clarify the resistance mechanism through gene testing and tissue/liquid biopsy. If targetable secondary mutations are found, doctors will prioritize the use of other targeted drugs. For example, if MET amplification occurs, moboxetinib may be considered in combination with MET inhibitors (such as capmatinib, tepotinib); if the downstream KRAS or PI3K pathway is found to be activated, the combined use of related targeted drugs in clinical trials can be explored. This personalized combination treatment based on drug resistance mechanisms is expected to delay disease progression and improve efficacy.

3. Reintroduction of chemotherapy and immunotherapy

For patients who have completely lost sensitivity to mobosertinib, traditional cytotoxic chemotherapy is still an important option if there is a lack of clear resistance targets. Regimen based on platinum doublets (such as pemetrexed combined with cisplatin or carboplatin) can control disease progression to a certain extent. In addition, some patients can still benefit from immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) after drug resistance, especially those with higher expression of PD-L1 in tumor tissue or higher tumor mutation burden (TMB). In clinical practice, chemotherapy combined with immunotherapy is also being explored to improve overall efficacy and survival.

4. Opportunities for clinical trials and new generation drugs

For patients with complete drug resistance, participating in clinical trials is a valuable option. Currently, there are several new generation EGFRexon20 insertion mutation inhibitors under development, such as CLN-081, Sunvozertinib (DZD9008), Poziotinib , etc., which have shown some activity against moboxetinib-resistant cases in preliminary studies. In addition, bispecific antibody drugs under development (such as Amivantamab, targeting EGFR and MET) have shown considerable response rates in clinical trials for patients with exon 20 mutations and drug resistance. These new drugs and treatment modalities may provide new hope for patients suffering from drug resistance.

5. Individualized treatment and patient management

In addition to drug selection, comprehensive management of drug resistance is equally important. First of all, doctors should develop an individualized plan based on the patient's overall physical condition, organ function, past medication history, and drug resistance mechanism . Secondly, patients should maintain regular follow-up examinations, including imaging evaluation and molecular testing, to detect new mutations or signs of progression in a timely manner. At the same time, supportive care cannot be ignored, such as nutritional support, symptom control, and psychological counseling, which can help patients maintain a better quality of life and improve tolerance to subsequent treatments.

Mobosetinib is a milestone in the treatment of lung cancer with EGFRexon20 insertion mutation, but drug resistance is inevitable. Once complete resistance occurs, clinical adjustments can be made through combination therapy after molecular typing, replacement of targeted drugs, introduction of chemotherapy and immunotherapy, and participation in clinical trials. In the future, as more new drugs are launched and combination strategies mature, the treatment landscape for patients with resistance to mobosetinib will become more diversified and precise, bringing longer survival benefits to patients.

Reference materials:https://www.drugs.com/